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Abstract. IQGAP1 is a scaffolding protein that serves a key 
role in cell dynamics by integrating internal and external 
stimuli to distinct signal outputs. Previous studies have identi-
fied several genes that are significantly up‑ or downregulated 
in the peripheral white cells (PWCs) of patients with colorectal 
adenocarcinoma (CRC), who underwent oxaliplatin‑based 
chemotherapy (CT). In addition, screening studies have 
reported that IQ-motif containing GTPase activating protein 1 
(IQGAP1) transcriptional expression levels varied from ‘off’ 
to ‘on’ following oxaliplatin CT. In order to determine if varia-
tions previously described in PWCs are able to be observed at 
the protein level in tumors and in metastases following CT, the 
present study performed an immunohistochemical analysis of 
IQGAP1 in CRC and primary metastases. IQGAP1 expres-
sion was observed in the nuclear envelope and in lateral cell 
membranes and cytoplasm in normal colon tissue. However, 
in tumor tissue, cells exhibited a diffuse pattern, with variable 
expression levels of staining in the nuclear membrane and 
cytoplasm, with the highest expression intensity observed at the 
invasive front. In healthy and metastasized liver tissue and in 
the metastases themselves, expression levels varied from cell to 
cell from no expression to a high level. In the majority of cells, 
IQGAP1 co‑localized with microtubules at the cytoplasmic 
face of the nuclear envelope. Strong positive expression was 
observed in areas of the lesion where cells were detaching from 
the lesion into the lumen. Despite the homogeneous IQGAP1 
staining pattern observed in healthy colon tissue sections, 
CRC demonstrated heterogeneity in staining, which was more 
marked in metastasized liver tissue resected following CT. 
However, the most notable findings were the observed effects 
on the cellular and subcellular distribution and its implications 
for cancer biology. These results suggest that IQGAP1 may be 
a putative biomarker, a candidate for clinical diagnostics and a 
potential novel target for anti-cancer therapeutics.
Introduction
Folinic acid, leucovorin, 5-fluorouracil and oxaliplatin 
(FOLFOX)‑based chemotherapy (CT) is widely used in the 
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treatment of colorectal adenocarcinoma (CRC). The addi-
tion of the platinum-containing compound oxaliplatin to 
the standard adjuvant treatment with 5‑fluorouracil plus 
leucovorin enhances the efficacy of CT, doubling the response 
rate and prolonging progression‑free survival of patients with 
stage II‑III CRC (1,2). Despite positive results obtained from 
this chemotherapeutic regimen, unwanted side effects are 
significant and require monitoring, as they affect, to various 
degrees, the quality of patient.
In an attempt to identify biomarkers that may predict the 
onset of these secondary effects, a recent study investigated the 
differential gene expression of peripheral leukocytes in patients 
with CRC prior to and following 3 cycles of oxaliplatin‑based 
CT (3). The study identified 502 differentially‑expressed genes 
that were significantly up‑ or downregulated in the peripheral 
white cells (PWCs) of patients following CT treatment (3).
To determine whether the changes in gene expression 
observed in PWCs may be detected in tumors following the 
administration of adjuvant CT, the present study performed 
immunohistochemical analysis of a selected number of genes 
that had previously been identified in the differential tran-
scriptome profile (4). The study observed that one gene among 
four, whose transcriptional expression levels varied from ‘off’ 
to ‘on’, was that coding for IQ‑motif containing GTPase acti-
vating protein 1 (IQGAP1) (3).
IQGAP1 is a ubiquitously expressed scaffold protein, 
which contains a number of protein interaction domains (5). 
The protein interacts with cell adhesion molecules, compo-
nents of the cytoskeleton, and various signaling molecules to 
regulate cell motility and morphology, cell cycle and other 
cellular functions (5,6). By regulating its binding partners, 
IQGAP1 integrates a number of signaling pathways, several 
of which contribute to tumorigenesis. For example, IQGAP1 
is associated with actin dynamics by direct binding to actin 
or indirect regulation via cell division cycle 42/Rac1 (7). 
Through its polyproline protein‑protein domain (WW 
domain), the protein modulates the mitogen‑activated 
protein kinase (MAPK) pathway, which is associated with 
cell cycle control (8). Therefore, IQGAP1 links MAPK 
signaling (for example, decisions regarding cell fate) to 
the cytoskeleton or cellular adhesion, with important 
implications for cancer.
Furthermore, interactions of IQGAP1 with extracel-
lular signal‑regulated kinases 1/2 and MEK1/2 may lead to 
activation of the MAPK signaling pathway, thus modulating 
cell differentiation and proliferation (8). Therefore, IQGAP1 
serves pivotal roles in several cellular functions, including 
control of polarization, cell adhesion, migration, proliferation 
and angiogenesis.
Numerous immunohistochemical studies have demon-
strated that IQGAP1 is overexpressed in several forms of 
cancer and an aberrant membrane accumulation is observed, 
particularly at the invasive front (9,10). Higher expression and 
altered localization of IQGAP1 from the cytoplasm to the 
membrane correlates with tumor grade and poor prognosis (11). 
The presence of IQGAP1 in the cell membrane may decrease 
adherens junction (AJ) function, favoring dissociation of the 
tumor cells (12).
The present study reports the alteration of IQGAP1 expres-
sion in CRC and liver metastases following CT administration 
at the protein level by performing an immunohistochemical 
analysis.
Patients and methods
Patients. The study was approved by the Ethics Committee 
of La Laguna University (La Laguna, Canary Islands, Spain) 
and the Ethical Committee of Nuestra Señora de Cande-
laria University Hospital (HUNSC; Santa Cruz de Tenerife, 
Canary Islands, Spain). All patients were treated at University 
Hospital of the Nuestra Señora de Candelaria, Santa Cruz 
de Tenerife, Spain between May 2007 and September 2015 and 
provided informed consent for the diagnosis and research of 
tissue specimens prior to enrollment in the study. All patients 
had colonic cancer and liver metastasis, which had been treated 
with FOLFOX‑CT, (day 1, oxaliplatin 100 mg/m2 iv over 2 h; 
leucovorin calcium 400 mg/m2 iv over 2 h; followed by 5‑fluo-
rouracil 400 mg/m2 iv bolus and by 5‑fluorouracil 2400 mg/m2 
iv over 46 h; every 14 days). All patients received CT following 
resection of the primary tumor. Therefore, the primary tumors 
were CT‑naïve, while the liver metastases were CT‑treated.
Tumor tissue. Paraffin‑embedded tissue samples from 15 patients 
(7 males and 8 females), ensuring patient's anonymity, and the 
corresponding clinical data were obtained from the reference 
medical areas of HUNSC.
Antibodies. The following antibodies were used: Rabbit 
anti‑human polyclonal antibody against IQGAP1 (dilutions, 
1:500 for immunohistochemistry and 1:250 for immuno-
fluorescence; cat. no. ABT186; EMD Millipore, Billerica, 
MA, USA); mouse monoclonal antibody clone PC10 against 
anti‑proliferating cell nuclear antigen (PCNA; dilution, 1:100; 
cat. no. 1486772; Roche Diagnostics GmbH, Mannheim, 
Germany); mouse monoclonal anti‑human cluster of differ-
entiation (CD)34 class II clone QBEnd 10 (ready‑to‑use; cat. 
no. IR632; Dako; Agilent Technologies GmbH, Waldbronn, 
Germany); and mouse monoclonal anti‑β tubulin (dilution, 
1:150; cat. no. sc-101527; Santa Cruz Biotechnology, Inc., 
Dallas, TX, USA). Secondary antibodies: Biotin‑conjugated 
anti‑rabbit secondary antibody (dilution, 1:300; cat. no. 31820; 
Pierce; Thermo Fisher Scientific, Inc., Waltham, MA, USA); 
fluorescein isothiocyanate (FITC)‑conjugated goat polyclonal 
antibody against rabbit IgG (cat. no. F9887; Sigma‑Aldrich, 
Merck Merck Millipore, Darmstadt, Germany; dilution, 1:200); 
goat polyclonal antibody against mouse IgG (DyLight® 650; 
cat. no. ab97018; Abcam, Cambridge, UK; dilution, 1:100).
Immunohistochemistry. Immunoperoxidase staining of 
paraffin‑embedded tissue sections (fixed in 10% formalin, 
for 48‑72 h at 4˚C) was performed using the avidin‑biotin 
reaction. Briefly, 5‑µm‑thick tissue sections were deparaf-
finized in xylene and hydrated in a graded series of alcohol 
baths. Heat‑induced epitope retrieval was achieved by heating 
samples in sodium citrate buffer (pH 6.0) at 120˚C for 10 min 
in an autoclave. Once non‑specific sites were blocked with 
5% non‑fat dry milk in TBS for 1 h at room temperature, endog-
enous biotin was blocked using the Avidin/Biotin Blocking kit 
(Vector Laboratories Inc., Burlingame, CA, USA). The primary 
antibody against IQGAP1 was applied (dilution, 1:500) to 
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slides over night at 4˚C. To block endogenous peroxidase 
activity, the slides were incubated with 3% hydrogen peroxi-
dase in methanol for 15 min. Biotin-conjugated anti-rabbit 
secondary antibody (dilution, 1:300; Pierce; Thermo Fisher 
Scientific, Inc., Waltham, MA, USA) was incubated for 2 h at 
37˚C, and ABC Peroxidase Staining kit (Thermo Fisher Scien-
tific, Inc.) was used to amplify the specific antibody staining. 
3,3'‑diaminobenzidine substrate concentrate (no. IHC‑101F; 
Bethyl Laboratories Inc., Montgomery, TX, USA) was used to 
visualize immunohistochemical reactions. Samples incubated 
without primary antibodies were used as a negative control. 
Slides were counterstained with Harris hematoxylin solution 
DC (Panreac Química SLU, Barcelona, Spain) to visualize cell 
nuclei and mounted with Eukitt mounting medium (Panreac 
Química SLU). An optical light microscope (BX50; Olympus 
Corporation, Tokyo, Japan) was used to visualize the results of 
the immunostaining.
Image analysis and statistical analysis. To compile tables, 
two independent observers evaluated the specimens blindly. 
Staining intensities were graded as absent (‑), weak (+), 
moderate (++) or strong (+++). These cut‑offs were established 
by consensus between each investigator following an initial 
survey of the entire blind‑coded material. In cases where scor-
ings differed by more than one unit, the observers re-evaluated 
the specimens to reach a consensus. In other cases, means of 
the scorings were calculated.
Double immunof luorescence simultaneous staining. 
Following deparaffinization, hydration and a heat‑induced 
epitope retrieval procedure (as described above), tissue 
sections were incubated simultaneously with a mixture of 
two distinct primary antibodies (rabbit anti‑human polyclonal 
antibody against IQGAP1 and mouse monoclonal antibody 
anti-PCNA, anti-CD34 or anti-β‑tubulin) overnight at 4˚C. 
Slides were then incubated for 1 h at room temperature in 
the dark with a mixture of two secondary antibodies raised 
in different species and conjugated to two different fluoro-
chromes [anti‑rabbit fluorescein isothiocyanate‑conjugated 
antibody (Sigma‑Aldrich; Merck Millipore) and anti‑mouse 
DyLight®650‑conjugated antibody (Abcam)]. Slides were 
mounted with ProLong® Diamond Anti‑fade Mountant with 
DAPI (Molecular Probes®; Thermo Fisher Scientific, Inc.) to 
visualize cell nuclei. Slides were analyzed using a confocal 
microscope (FV1000; Olympus Corporation).
Results
IQGAP1 expression and localization in healthy colon and CRC 
tissue sections. Fig. 1 demonstrates IQGAP1 immunoreactivity 
Figure 1. Immunohistochemical analysis of IQGAP1 protein expression in normal colon and colon adenocarcinoma tissue sections. (A) In normal colon 
tissue, positive staining was observed in the nuclear membrane, and in the lateral cell membrane and cytoplasm. (B) Tumor exhibiting heterogeneous IQGAP1 
localization in the cytoplasm, nuclear membrane and plasma membrane. Arrowheads point to intense apical cell membrane staining, while arrows indicate 
budding tumor cells. (C) Low magnification of a CRC tumor section demonstrating a higher grade of IQGAP1 expression at the invasive front (arrowhead). 
(D) Tumor glands exhibiting a polarized positive signal. Cells located at the invasive front exhibited a strong membranous staining (arrows). (E) Tumor 
budding at the invasive front. Arrows identify open lumen lymphatic ducts with disseminated cancer cell nests. Nests demonstrated variable staining in the 
cytoplasm and nuclear envelope. Arrowhead points to the invasive lesion. (F) Cancer cell clusters with intense membranous staining (arrows) and lighter 
staining in cytosol. (G) Intense immunopositivity in a tumor gland exhibiting diffused localization (cytoplasm and nuclear membrane). Note the strong apical 
localization (arrowheads). Arrow points to unstained cells intermixed with IQGAP1+ cells. (H‑K) Arrowheads identify budding tumor cells. Arrows point 
to IQGAP1+ immune cells associated with budding cells. Micrographs in the assembled figure were selected from different CRC cases. IQGAP1, IQ‑motif 
containing GTPase activating protein 1; CRC, colorectal adenocarcinoma.
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in paraffin‑embedded sections of normal colon and in healthy 
areas of adenocarcinoma sections. The signal revealed positive 
staining in enterocytes (nuclear membrane, cytoplasm, apical 
and lateral cell membrane) (Fig. 1A); the majority of cells were 
stained and only a few exhibited a lighter level of staining. 
IQGAP1 protein was localized in cytoplasm, nuclear enve-
lope, cell junctions, plasma membrane and apical membrane, 
and this variable localization could be observed in the same 
structure concurrently (Fig. 1B and D‑F). Within the tumor, 
tumor cells exhibited a diffuse pattern with a variable level 
of staining (from no staining to high intensity) in the nuclear 
envelope and in the cytoplasm. The intensity of staining was 
higher at the invasive front (Fig. 1C). Cancer cell nests exhib-
ited variable positive perinuclear and cytoplasmic staining 
in the open-lumen lymphatic ducts located in the submucosa 
(Fig. 1B and E, black arrows). In Fig. 1D, the intense membra-
nous IQGAP1 staining appeared polarized in several tumor 
glands, while the other cells of the lesion were negative or 
exhibited only weak reactivity. Thus, the expression pattern 
and localization of IQGAP1 protein in the CRC tissue sections 
was heterogeneous, both in the normal glandular epithelium 
and in tumor glands and nests. Strongly IQGAP1-positive 
cells were intermixed with unstained tumor cells within 
tumor lesions (Fig. 1G, black arrow); in several carcinoma cell 
clusters located in close proximity to tumor glands, a strong 
and diffuse membranous immunolocalization was observed, 
while nuclei were negative (Fig. 1F, black arrows). In several 
lesions, strong apical cell membrane staining was observed 
(arrowhead in Fig. 1G); in addition, strong IQGAP1 expression 
was observed in areas of the lesion where cells were detaching 
into the lumen (asterisk in Fig. 1G).
Fig. 1H‑K shows representative images of budding tumor 
cells (arrowheads) either as small clusters of cells (<5 cells) 
or as single cells. IQGAP1 expression was variable, with 
certain cells exhibiting a strong positive signal all along the 
cell membrane, while others were completely negative. The 
presence of IQGAP1+ immune cells (arrows) was associated 
with budding cells.
IQGAP1 expression and localization in healthy and metas-
tasized liver tissue sections. In healthy liver and the healthy 
region of metastasized liver tissues, hepatocytes exhibited a 
clearly delimitated labeling in the plasma membrane, cyto-
plasm and nuclear envelope, exhibiting non-homogenous 
IQGAP1+ immunostaining, with neighboring hepatocytes 
demonstrating variable levels of expression (Fig. 2). Along 
the tissue sections, there were areas with no signal and areas 
exhibiting variable positive staining. The intensity of the 
signal was higher in the metastasized tissue sections compared 
with normal liver sections (Fig. 2A and B). Bile ducts exhib-
ited weak apical staining in normal liver sections (Fig. 2C), 
while in metastasized liver sections they demonstrated intense 
membranous positive staining (Fig. 2D).
Metastases exhibited variable levels of IQGAP1 expression, 
and were heterogeneous in terms of intensity and localization 
(Fig. 2E‑G). Positive immunostaining was observed in several 
Figure 2. Immunohistochemical analysis of the expression of IQGAP1 in liver tissues. (A and B) Immunohistochemical staining demonstrated variable 
expression of IQGAP1 in hepatocytes in (A) healthy tissues and (B) a healthy area of metastasized liver tissue. Note that neighboring hepatocytes exhib-
ited significantly different levels of expression. (C) Normal liver bile ducts with weak apical staining. (D) Metastasized liver portal trial with an intense 
positive membranous staining in bile ducts. (E) Metastases exhibited variable positive staining. Arrows point to malignant cells with strong membranous 
staining, while arrowheads point to areas of apical cell region staining. (F) Tumor glands demonstrated IQGAP1+ membranous staining. (G and H) Several 
microvessels exhibited a strong positive signal (arrows), while other vessels appeared negative (arrowheads). (I) Several stromal cells and microvessels located 
between lesions exhibited intense positive staining. (J) Higher magnification of the inset in (I); arrow points to an IQGAP1+ tumor-associated microvessel. 
(K and L) IQGAP1- tumor cells with tumor‑associated fibroblast‑like cells exhibited strong IQGAP1 staining. IQGAP1, IQ‑motif containing GTPase activating 
protein 1.
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stromal cells (Fig. 2H‑L) and in microvessels present in areas 
adjacent to the metastasis (Fig. 2G and H). To assess the nature 
of these IQGAP1+ vessels, the vascular endothelium marker 
CD34 was used. Confocal analyses of tissue sections double 
immune-labeled for CD34 and IQGAP1 revealed co-localiza-
tion of each protein in several vessels (Fig. 3A‑E).
Tables I and II specify the IQGAP1 expression signatures 
observed in the tissue specimens.
To evaluate the proliferative activity of tumor cells, the 
proliferation marker PCNA was used in double immunofluo-
rescence experiments on formalin‑fixed, paraffin‑embedded 
tissue sections. In several malignant cells forming tumor nests, 
IQGAP1 and PCNA protein exhibited partial co-localization. 
The distribution of intranuclear PCNA and IQGAP1 surrounding 
the outer membrane of the nucleus suggests that these cells were 
in the early S phase (Fig. 3F‑I).
In Fig. 3J-M, IQGAP1+ staining was observed along the 
cell membrane of several tumor cells, and in tumor-associated 
blood and microvessels. Within the lesion, PCNA intensity 
and localization varied depending on the stage of the cell 
cycle in which the cells were. Notably, IQGAP1+ staining was 
frequently observed in cells in G1/S phase when PCNA begins 
to translocate from the cytoplasm to the nucleus (Fig. 3F‑I), or 
in cells in early S phase when PCNA expression in the nucleus 
is weaker (Fig. 3J‑M, yellow arrowhead). High levels of PCNA 
in the nucleus helps to identify late S phase cells; within these 
cells, no IQGAP1+ signal was observed (Fig. 3J‑M, white 
arrowhead), except occasionally in the nucleolus (Fig. 3Q).
Given the key role of IQGAP1 in the regulation of the 
cytoskeleton, double immunofluorescence experiments were 
performed on CRC tissue sections to localize IQGAP1 and 
β-tubulin. As presented in Fig. 4, IQGAP1 co‑localized with 
Figure 3. Confocal microscopic analysis of the protein expression by double immunostaining on paraffin‑embedded tissue sections of CRC and metastasized 
liver for IQGAP1 (green) and CD34 (red) or PCNA (red) and DAPI. CRC tissue section; arrows point to tumor‑associated vessels with positive staining for 
(A) IQGAP1 and (B) CD34 or (C) IQGAP1 and CD34 colocalization. Tumor‑associated microvessels in (D) metastasized liver and in (E) CRC tissue sections. 
IQGAP1+ CD34+ microvessels are identified by arrows. (F‑I) Metastasized liver double immunostaining for (F) IQGAP1 (green) and (G) PCNA (red). IQGAP1 
and PCNA co‑localized at the outer nuclear membrane in several cells of the tumor nests; (H) IQGAP1 and PCNA co‑localization (I) in addition to DAPI. 
(J‑M) Metastasized liver section double immunostaining for IQGAP1 (green) and PCNA (red). Thin arrow points to a tumor cell cluster where IQGAP1 
was observed along the cell membrane; note the presence of a PCNA+ cell in the cluster. Yellow arrow points to an IQGAP1+ tumor-associated microvessel. 
Thick white arrow points to tumor‑associated blood vessel with PCNA labeled endothelial cells. Yellow arrowhead points to an IQGAP1+ PCNA+ tumor cell. 
White arrowhead points to an IQGAP1- PCNA+ tumor cell. (N‑Q) CRC tissue section double immunostaining for (N) IQGAP1 (green) and (O) PCNA (red); 
(P) DAPI; (Q) IQGAP1 and PCNA colocalization. Note the positive IQGAP1 staining in the nucleoli of tumor cells (arrows). Scale bar, 50 µm. IQGAP1, 
IQ-motif containing GTPase activating protein 1; CD, cluster of differentiation; PCNA, proliferating cell nuclear antigen; CRC, colorectal adenocarcinoma.
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microtubules at the cytoplasmic face of the nuclear envelope 
in certain cells (arrows). However, in other cells, the pole of 
the cell was stained for IQGAP1 with no label for β-tubulin. 
Nucleolar staining was often observed throughout the fields of 
observation (Figs. 1-4).
Discussion
The present study aimed to study the expression of IQGAP1 in 
CRC and liver metastases following the administration of adju-
vant CT using immunohistochemistry. In contrast to normal 
cells, in which IQGAP1 was homogeneously distributed, 
cancer cells presented variable expression patterns, ranging 
from no expression to whole cell, high level of expression 
(Fig. 1A‑C). As shown in Fig. 1C, maximum expression was 
observed at the growing front of the tumor gland indicating 
the expanding direction, which corresponded to the apical 
region of the expanding cell in which nuclei were in the 
opposite pole. Furthermore, double labeling by IQGAP1 and 
β-tubulin demonstrated that in certain tumor cells the asso-
ciation of each protein disappeared (Fig. 4), indicating clear 
points where epithelial to mesenchymal cell transition (EMT) 
occurs. This supports the role of IQGAP scaffold proteins 
in the regulation of membrane dynamics by coupling the 
cortical actin meshwork to microtubules via plus‑end binding 
proteins and other proteins involved in intracellular signaling 
that, ultimately, results in modulation of more complex func-
tions, including cytokinesis, cell migration, cell growth or 
survival. Specifically, IQGAP1 is observed in actin‑dependent 
membrane structures (membrane ruffles implicated in cell 
locomotion and lamellipodia) interacting with the plus‑end 
binding proteins cytoplasmic linker protein-170 and adenoma-
tous polyposis coli (APC), tethering microtubules to the actin 
network (13,14). Furthermore, in the nuclear envelope of certain 
tumor cells, co-expression of IQGAP1 protein and β-tubulin 
was observed (Fig. 4). This co‑localization of IQGAP1 
with the microtubule network at the cytoplasmic face of the 
nuclear envelope has previously been described by Johnson 
and Henderson (15) in MCF‑7 (breast cancer epithelial cells), 
HT29 (colon cancer epithelial cells) and NIH3T3 (non‑tumor 
embryonic fibroblasts) cell lines, and was also correlated with 
a possible role for IQGAP1 in cell polarization and migration 
events, in addition to cell cycle-associated nuclear envelope 
assembly/disassembly. Johnson and Henderson (15) suggested 
that interactions between IQGAP1 and microtubules may 
tether these cytoskeletal networks to perinuclear actin via the 
Figure 4. Confocal microscopic analysis of (A) IQGAP1 (green) and 
(B) β‑tubulin (red) expression by double immunofluorescence staining on 
CRC tissue sections. (C) IQGAP1 and β‑tubulin colocalization and with 
(D) the addition of the nuclear stain DAPI. In the majority of cells, IQGAP1 
co‑located with microtubules at the cytoplasmic face of the nuclear envelope 
(arrows). Note that several cells exhibited increased IQGAP1 expression at 
the plasma membrane (arrowhead) at areas with no (or extremely low) tubulin 
expression. IQGAP1, IQ-motif containing GTPase activating protein 1.
Table I. IQGAP1 expression and localization in healthy colon 
and CRC tissues.
Cell type Healthy colon CRC
Epithelial cells (Mucosae) +++ +++/‑
 lm, am, n, c pm, lm, c, n
Stromal cells (Mucosae) ‑ ++/‑
Tumor cells ‑ +++/‑
  pm, c, n
Tumor associated stromal cells ‑ ++/‑
Immune cells ? +++
Endothelial cells ++ ++
 n n, c
Smooth muscle cells ++ ‑
 n 
Neurons (Myenteric plexus) ++ ‑
Glial cells (Myenteric plexus) ++ ‑
‑, negative; ++, moderate; +++, high; ++/‑, variable from moderate to 
absent; +++/‑, variable from high to absent; ?, indeterminate staining; 
lm, lateral membrane; am, apical membrane; pm, plasma membrane; 
c, cytoplasm; n, nucleus or nuclear envelope.
Table II. IQGAP1 expression and localization in healthy and 
colorectal adenocarcinoma metastasized liver.
Cell type Healthy liver Metastasized liver
Tumor cells  ‑ ++/‑
  pm, c 
Hepatocytes +++/‑ +++/‑
 n, c n, c
Epithelial cells + ++
(bile ducts) am pm
Tumor associated ‑ ++
stromal cells  
‑, negative; +, weak; ++, moderate; +++, high; ++/‑, variable from 
moderate to absent; +++/‑, variable from high to absent; am, apical 
membrane; pm, plasma membrane; c, cytoplasm; n, nucleus or 
nuclear envelope.
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plus‑end protein APC and/or interaction with other nuclear 
envelope proteins to regulate the microtubule organizing 
center and nuclear positioning for cell polarization during cell 
migration, a key process in tumorigenesis and carcinogenesis.
In the current study, increased expression and altered 
localization of IQGAP1 from the cytoplasm to the plasma 
membrane was observed in several tumor cells compared 
with healthy tissue (Figs. 1D, F and H, 2E and 4) may serve 
to decrease AJ stability, favoring dissociation of the tumor 
cells (12). IQGAP1 at the plasma membrane regulates the 
stability of the AJ complex, which is necessary for proper 
apical-basal polarity of epithelial cells that disappears during 
the EMT process (16).
In the present study, the co-localization of CD34 and 
IQGAP1 in several vessels (Fig. 3A‑E) is indicative of a 
role for IQGAP1 in tumor vasculogenesis and/or in vascular 
invasion. Nakhaei-Nejad et al (17) studied the involvement of 
endothelial IQGAP1 in leukocyte transendothelial migration, 
and demonstrated, by RNAi silencing of IQGAP1 in human 
umbilical vein endothelial cells, that IQGAP1 and interen-
dothelial junction‑associated microtubules were involved in 
remodeling interendothelial junctions to facilitate lymphocyte 
diapedesis under physiological shear stress. Furthermore, 
Yamaoka-Tojo et al (18) reported that IQGAP1 is a novel 
vascular endothelial growth factor receptor 2 (VEGFR2) 
binding protein in quiescent endothelial cells and is important 
for the establishment of VE-cadherin-based cell-cell contacts, 
and suggested that IQGAP1 may function as a scaffold linking 
VEGFR2 to the β-catenin/VE-cadherin compound at the 
AJ (18).
PCNA is a DNA clamp that increases the processivity of 
DNA polymerase δ in eukaryotic cells, which is used as a 
marker of proliferating cells (19-21). The immunohistochem-
ical experiments of the present study revealed that certain cells 
co‑expressed IQGAP1 and PCNA in the cytoplasm, whereas 
others expressed IQGAP1 in the cytoplasm and PCNA in the 
nucleus, which is indicative of S phase (22). In addition, CD34+ 
microvessels of CRC and metastatic sections co-express PCNA 
and IQGAP, while the majority of cancer cells do not contain 
intranuclear PCNA, though they may contain cytoplasmic, 
pointing to a quiescent phase while waiting for energy to be 
supplied in order for the carcinogenic process to progress (23).
As shown in Fig. 3F-M, during the synthesis of PCNA, 
PCNA and IQGAP1 are simultaneously expressed in the 
cytoplasm of cells within the liver. PCNA then enters into the 
nucleus and S phase of mitosis begins. A role for IQGAP1 in 
regulating early S phase replication events has been recently 
proposed. Johnson et al (23) identified nuclear localization of 
IQGAP1 in several mammalian cell lines. This nuclear local-
ization was low in asynchronous cells, but was significantly 
increased in cells arrested in G1/S phase (23). The authors 
suggested that the protein enters the nucleus at G1/S phase 
and exits in late S phase. Furthermore, nuclear IQGAP1 was 
identified to function as part of a complex with replication 
protein A 32 kDa subunit and PCNA, suggesting a functional 
role for IQGAP1 in the reinitiation of S phase following DNA 
replication arrest (23).
As observed in the current study, nucleoli staining is often 
observed throughout the field of microscopic observation, 
which is consistent with Bielak‑Zmijewska et al (24). The 
authors observed the presence of IQGAP1 in mouse oocyte 
nuclei, forming a ring around the nucleolus only in transcrip-
tionally active oocytes, but not in transcriptionally silent ones 
or in growing oocytes treated with the transcription inhibitor 
α‑amanitin, indicating an association between IQGAP1 
expression in the nucleolus and RNA synthesis (24).
In conclusion, extremely few studies have analyzed 
IQGAP1 expression in colorectal tumors, and none have yet 
addressed IQGAP1 expression in CRC and its associated liver 
metastases. To the best of our knowledge, the present study 
is the first to provide a detailed analysis of IQGAP1 expres-
sion in CRC tissue sections and metastasized liver tissue 
samples, which were resected following oxaliplatin‑based 
CT. Despite the homogeneous IQGAP1 staining pattern 
observed in healthy colon tissue sections, the CRC tissues 
exhibited heterogeneous expression (in terms of localization 
and intensity), which was more marked in the metastasized 
liver sections resected following CT treatment. However, more 
notable findings are the described effects over the cellular 
and subcellular distribution and its implications in the cancer 
biology. Therefore, IQGAP1 may be a novel cancer antigen, 
a surrogate biomarker of responses to CT, a candidate for the 
development of new clinical diagnostics and a new target for 
anti-cancer therapeutics.
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